A new topical treatment proven to reduce facial redness was recently approved by Health Canada. ONRELTEA™ gel (Brimonidine gel 0.33%) is available to rosacea patients age 18 and older to treat persistent facial erythema (redness) caused by rosacea.
Rosacea is a chronic, inflammatory skin condition that affects an estimated 2 million Canadians. Characterized by facial redness, visible facial blood vessels, pimple-like bumps and blemishes that typically appear in the middle of the face (forehead, nose, cheeks), rosacea is most evident in patients over the age of 30. While treatments exist for the inflammatory bumps and blemishes of rosacea, ONRELTEA is specifically developed and indicated to treat facial redness, which is the most common symptom of the condition. “Despite many rosacea treatment advancements, patients were still left without any options when it came to controlling the redness,” notes Dr. Rivers. “Redness is by far the most bothersome symptom for rosacea patients. ONRELTEA has been shown to reduce redness for up to 12 hours.”
How it Works
ONRELTEA gel is easy to apply and provides greater control over redness. The gel works by constricting the dilated facial blood vessels to reduce the redness of rosacea. For many patients, the product will start to relieve the facial redness within 30 minutes after application, with maximum effect at about 3 hours.
Proven Results
The approval of ONRELTEA was based on data collected from more than 550 patients who participated in two clinical studies of one month in duration. The results from both studies showed that adults who used ONRELTEA demonstrated significantly greater improvement in the facial redness of rosacea. A long-term study was also conducted involving 449 subjects who used ONRELTEA for up to 12 months, which showed that the treatment was effective and well tolerated.